Researchers Aim to Confirm Benefits of Non-Hormonal Therapy for Certain Prostate Cancer Patients
A Phase II trial showed AstraZeneca's Lynparza (olaparib) effective in treating recurrent prostate cancer without hormone therapy, prompting larger follow-up studies in biomarker-selected subgroups. Lynparza, a PARP inhibitor, demonstrated efficacy in patients with homologous recombination repair gene mutations, particularly BRCA2, with higher response rates than seen with hormonal suppression. The study suggests that not all prostate cancer patients need hormone therapy and highlights the need for biomarker-selected trials to identify responders.
Reference News
A Phase II trial showed AstraZeneca's Lynparza (olaparib) effective in treating recurrent prostate cancer without hormone therapy, prompting larger follow-up studies in biomarker-selected subgroups. Lynparza, a PARP inhibitor, demonstrated efficacy in patients with homologous recombination repair gene mutations, particularly BRCA2, with higher response rates than seen with hormonal suppression. The study suggests that not all prostate cancer patients need hormone therapy and highlights the need for biomarker-selected trials to identify responders.